Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis

Adam S Kittai; Ying Hang; Seema A Bhat; Abi Clark; Michael Grever; Joanna M Rhodes; Melyssa Roberts; Kerry A Rogers; Anna Teschemaker; Maria Munoz-Sagastibelza; Jennifer A Woyach; Jacqueline C Barrientos

doi:10.1002/ajh.27241

Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis

Am J Hematol. 2024 Apr;99(4):780-784. doi: 10.1002/ajh.27241. Epub 2024 Feb 15.

Affiliations

¹ Division of Hematology, The Ohio State University, Columbus, Ohio, USA.
² US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.
³ Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
⁴ Global Evidence Generation, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.
⁵ Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA.
⁶ Mount Sinai Comprehensive Cancer Center, Miami, Florida, USA.

PMID: 38357757
DOI: 10.1002/ajh.27241

Abstract

Kaplan-Meier curve depicting overall survival from CLL treatment start by race. For patients with CLL, no overall survival difference was observed between races in this real-world US database.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cohort Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell*

Grants and funding

AstraZeneca